FIELD: immunology.
SUBSTANCE: what is presented is a pharmaceutical combination of obinutuzumab and an inhibitor of BTK, selected from a group consisting of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or its salts. Also disclosed is a method of treating and using the combination.
EFFECT: present invention can find further application in therapy of various types of cancer, in which CD20 expression takes place, particularly lymphoma or lymphocytic leukemia.
9 cl, 5 dwg, 7 tbl, 3 ex
